SFOODSNasdaq HelsinkiSpecialty ChemicalsIFRS · EUR

Solar Foods Oyj

Solar Foods is a Finnish food technology company built around the Solein protein ingredient, which is produced through a proprietary fermentation-based process rather than conventional agriculture. The business develops, manufactures, and commercializes protein raw materials and related applications for food and nutrition customers, with an international market focus.

Revenue0.1m EUR
+560.1 %y/y
Operating profit (EBIT)-10.4m EUR
−16.6 %y/y
EBIT margin-8,414.6%
+39,222.4 ppy/y
Net income-11.5m EUR
−4.5 %y/y

Fiscal year 2025 · change from previous year

Development 2022–2025

-12.5-10.0-7.5-5.0-2.50.02.5m EUR2022: EBIT -3.2 m EUR20222023: 0.00 m EUR2023: EBIT -6.8 m EUR20232024: 0.02 m EUR2024: EBIT -8.9 m EUR20242025: 0.12 m EUR2025: EBIT -10 m EUR20250.12-10
RevenueOperating profit (EBIT)

Business

Share of revenue
Solein ingredient70 %

Protein raw material sold for use in food and nutrition products.

Health & Performance Nutrition applications15 %

Application-specific concepts and formulations built around Solein.

Technology development and commercialization15 %

Development work tied to production process, organism platform, and scale-up.

Customers

Solar Foods sells into food and nutrition companies that need a high-protein ingredient with stable supply and a differentiated sustainability profile. The first target market highlighted in the reports is Health & Performance Nutrition, where customers value protein functionality, ingredient consistency, and non-animal sourcing. The company also serves product developers and brands that test Solein in consumer-facing concepts before broader commercialization.

Health & Performance Nutrition brands

Buy Solein for protein-rich nutrition products where functionality and supply stability matter.

Food manufacturers

Use Solein as an ingredient in broader food applications that need protein enrichment.

Consumer brands and formulators

Test and launch products using Solein-based concepts to validate market demand.

Alternative protein buyers

Seek non-animal protein inputs as an alternative to whey and other conventional sources.

Strategy

Solar Foods is focused on turning Solein from a technology platform into a commercial ingredient business, with Health & Performance Nutrition as the initial beachhead market. The company is also preparing for industrial scale-up through Factory 02, while strengthening its go-to-market organization and product application work to support customer adoption.

Commercialize Solein in Health & Performance NutritionShort term

This is the first target market and the main route to early revenue generation.

Expand production capacity through Factory 02Medium term

Scale-up is needed to support larger customer volumes and broader commercialization.

Strengthen product and application developmentMedium term

Customer adoption depends on proving functionality in real formulations.

Geography

Solar Foods is headquartered in Finland, but its commercial ambition is international and the reports explicitly highlight the United States as the first major target market. The company’s production and development footprint is tied to Finland, while future scale-up is linked to Factory 02. Geography matters because the business depends on access to global food customers, cross-border commercialization, and capital-intensive manufacturing capacity.

Risks

Solar Foods remains exposed to early-stage commercialization risk, including the possibility that demand ramps more slowly than expected before new capacity comes online. The business also depends on external financing, regulatory and customer adoption in new markets, and successful scale-up of a novel production process. As a food ingredient company, it faces competition from whey, plant-based proteins, and other alternative protein technologies.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Funding dependence1Slow commercialization before Factory 022Technology and scale-up execution3Competitive alternative proteins4Macroeconomic and geopolitical uncertainty5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Funding dependenceImpact: CriticalLikelihood: High

    The company needs additional capital, loans, and grants to finance commercialization and capacity build-out.

    Exposure: Corporate financing and dilution risk

  2. Slow commercialization before Factory 02Impact: HighLikelihood: High

    Meaningful revenue is expected to depend on future production capacity and customer adoption.

    Exposure: Revenue timing and scale-up risk

  3. Technology and scale-up executionImpact: HighLikelihood: Medium

    A novel fermentation-based protein process must work reliably at industrial scale.

    ExposureProduction yieldQualityCost risk
  4. Competitive alternative proteinsImpact: MediumLikelihood: Medium

    Customers can choose from whey, plant-based, and other emerging protein sources.

    Exposure: Pricing and market share pressure

  5. Macroeconomic and geopolitical uncertaintyImpact: MediumLikelihood: Medium

    Global trade disruption, tariffs, and conflict can affect customer demand and planning.

    Exposure: International market exposure

Accounting

Judgemental items
Capitalized development costs

Activated development spending depends on expected future revenues and can later require impairment if assumptions fail.

Impact: Affects intangible assets, operating expense, and future write-down risk

Government grants

Grants offset investment and development costs and can materially change reported capex and expense levels.

Impact: Reduces net investment and influences reported R&D intensity

Lease commitments

Long-term facility leases create significant off-balance-sheet style cash obligations under IFRS 16.

Impact: Affects lease liabilities, depreciation, and interest expense

Contingent VAT on property investment

The company must monitor VAT deductions on a completed property investment through the review period.

Impact: Could create a future liability if taxable use declines

Share-based compensation and option dilution

Option programs and equity-settled awards can dilute shareholders and affect equity accounting.

Impact: Affects equity, EPS dilution, and compensation expense

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026

Solar Foods Oyj (XHEL) – Specialty Chemicals | Financial Analysis – Clarifo